Market StrategyManagement highlights a new strategy focusing on entering less competitive areas with moderate-sized opportunities in immunology, which is expected to drive future growth.
Pipeline GrowthNovartis flagged over 15 submission-enabling readouts in the next two years, indicating potential future growth.
Product PerformanceNovartis upgraded the peak sales targets for key products like Kisqali, Cosentyx, Kesimpta, and Pluvicto.